TRCT
LLY icon

Tower Research Capital (TRC)’s Eli Lilly LLY Stock Holding History

Tower Research Capital (TRC)’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.1M Buy
21,848
+2,838
+15% +$2.88M 0.52% 24
2025
Q4 		$20.4M Buy
19,010
+8,372
+79% +$8.01M 0.49% 23
2025
Q3 		$8.12M Sell
10,638
-9,924
-48% -$7.39M 0.22% 78
2025
Q2 		$16M Sell
20,562
-7,578
-27% -$5.89M 0.43% 33
2025
Q1 		$23.2M Sell
28,140
-8,176
-23% -$6.8M 0.69% 16
2024
Q4 		$28M Buy
36,316
+16,057
+79% +$13.3M 0.56% 21
2024
Q3 		$17.9M Sell
20,259
-7,757
-28% -$6.97M 0.48% 24
2024
Q2 		$25.4M Buy
28,016
+7,651
+38% +$6.12M 0.43% 24
2024
Q1 		$15.8M Sell
20,365
-87,258
-81% -$62.1M 0.38% 38
2023
Q4 		$62.7M Buy
107,623
+76,160
+242% +$44.5M 0.77% 15
2023
Q3 		$16.9M Buy
31,463
+14,467
+85% +$7.45M 0.53% 22
2023
Q2 		$7.97M Buy
16,996
+2,920
+21% +$1.22M 0.27% 42
2023
Q1 		$4.83M Sell
14,076
-2,780
-16% -$938K 0.15% 79
2022
Q4 		$6.17M Sell
16,856
-53,808
-76% -$19.1M 0.26% 50
2022
Q3 		$22.8M Buy
70,664
+32,000
+83% +$10.1M 0.37% 43
2022
Q2 		$12.5M Sell
38,664
-67,003
-63% -$20.1M 0.28% 59
2022
Q1 		$30.3M Buy
105,667
+60,377
+133% +$15.5M 0.29% 62
2021
Q4 		$12.5M Buy
45,290
+30,412
+204% +$7.71M 0.22% 75
2021
Q3 		$3.44M Sell
14,878
-3,422
-19% -$845K 0.09% 154
2021
Q2 		$4.2M Sell
18,300
-65,550
-78% -$13.2M 0.11% 124
2021
Q1 		$15.7M Buy
83,850
+56,515
+207% +$11.1M 0.26% 69
2020
Q4 		$4.62M Buy
27,335
+13,388
+96% +$2M 0.14% 79
2020
Q3 		$2.06M Buy
13,947
+1,262
+10% +$195K 0.02% 370
2020
Q2 		$2.08M Buy
12,685
+11,885
+1,486% +$1.82M 0.09% 218
2020
Q1 		$111K Sell
800
-719
-47% -$98.8K 0.01% 956
2019
Q4 		$200K Sell
1,519
-11,276
-88% -$1.31M 0.02% 581
2019
Q3 		$1.43M Buy
+12,795
New +$1.42M 0.1% 184
2019
Q2 		– Sell
-13,192
Closed -$1.71M – 4006
2019
Q1 		$1.71M Sell
13,192
-17,170
-57% -$2.09M 0.1% 151
2018
Q4 		$3.51M Buy
30,362
+21,430
+240% +$2.39M 0.25% 83
2018
Q3 		$958K Sell
8,932
-20,513
-70% -$2.05M 0.07% 214
2018
Q2 		$2.51M Buy
+29,445
New +$2.42M 0.14% 131
2018
Q1 		– Sell
-3,091
Closed -$261K – 3582
2017
Q4 		$261K Buy
3,091
+2,655
+609% +$226K 0.03% 477
2017
Q3 		$37K Buy
436
+263
+152% +$21.6K ﹤0.01% 2246
2017
Q2 		$14K Sell
173
-3,862
-96% -$315K ﹤0.01% 1417
2017
Q1 		$340K Sell
4,035
-11,120
-73% -$891K 0.03% 194
2016
Q4 		$1.11M Buy
15,155
+13,153
+657% +$980K 0.12% 181
2016
Q3 		$161K Sell
2,002
-12,396
-86% -$992K 0.02% 588
2016
Q2 		$1.13M Buy
+14,398
New +$1.08M 0.11% 141
2016
Q1 		– Sell
-570
Closed -$48K – 4578
2015
Q4 		$48K Buy
+570
New +$47.3K 0.01% 588
2015
Q3 		– Sell
-2,946
Closed -$246K – 4435
2015
Q2 		$246K Sell
2,946
-9,931
-77% -$757K 0.02% 288
2015
Q1 		$935K Buy
12,877
+10,928
+561% +$778K 0.12% 113
2014
Q4 		$134K Sell
1,949
-18,770
-91% -$1.27M 0.01% 456
2014
Q3 		$1.34M Buy
20,719
+18,971
+1,085% +$1.2M 0.15% 126
2014
Q2 		$109K Sell
1,748
-292
-14% -$17.4K 0.01% 858
2014
Q1 		$120K Sell
2,040
-2,088
-51% -$117K 0.02% 622
2013
Q4 		$210K Sell
4,128
-15,345
-79% -$768K 0.04% 494
2013
Q3 		$980K Buy
19,473
+19,197
+6,955% +$1.01M 0.11% 172
2013
Q2 		$14K Buy
+276
New +$15K ﹤0.01% 2046

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Tower Research Capital (TRC)'s LLY Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Eli Lilly (LLY) stake by 15% in Q1 2026, buying an estimated $2.88M and bringing the position to 21,848 shares worth $20.1M. The position accounts for 0.52% of the portfolio, ranked #24.

Tower Research Capital (TRC) first reported a position in LLY in Q2 2013 and has held it in 48 quarters since. The position peaked at $62.7M in Q4 2023. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Tower Research Capital (TRC) held 21,848 shares of Eli Lilly worth $20.1M as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,838 Eli Lilly shares in Q1 2026, an estimated $2.88M.
  • Eli Lilly made up 0.52% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #24 holding.
  • Tower Research Capital (TRC) first reported a position in Eli Lilly in Q2 2013 and has held it in 48 quarters since.
  • Tower Research Capital (TRC)'s Eli Lilly position peaked at $62.7M in Q4 2023.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.